阿托伐他汀干预对急性心肌梗死患者血清IL-18和MMP-9水平的影响  

Effect of atorvastatin on IL-18 and MMP-9 level in patients with acute myocardial infarction

作　　者：艾民 张清华[2] 颜昌福 夏福纯 周双陆 贺剑 顾定平 付国齐 张宽 江军 李涛 杨景美 

机构地区：[1]攀钢总医院心内科,四川省攀枝花市617023 [2]中国人民解放军三0五医院,北京市100017

出　　处：《实用医学杂志》2013年第1期105-107,共3页The Journal of Practical Medicine

基　　金：全军医药卫生科研基金项目(编号:08Z017);国家自然科学基金项目(编号:30971235)

摘　　要：目的:观察阿托伐他汀对急性心肌梗死患者血清白介素-18(IL-18)和基质金属蛋白酶-9(MMP-9)表达水平的影响。方法:采用随机、双盲、对照的研究方法,将78例急性心肌梗死患者随机分为治疗组(阿托伐他汀20mg/d,连续用药14d)和普通组(除未用阿托伐他汀外,余治疗同治疗组)。药物治疗前及随访2个月后分别检测血清IL-18和MMP-9水平。结果:2个月后两组患者血清IL-18和MMP-9水平明显降低,治疗组39例患者经口服阿托伐他汀后2个月血清IL-18和MMP-9水平明显低于普通组(P<0.05)。结论:阿托伐他汀可显著降低急性心肌梗死患者血清IL-18和MMP-9水平,可作为治疗急性心肌梗死的新靶点。Objective To observe effect of atorvastatin on serum interleukin 18 （IL-18） and nmtrix metalloproteinases-9 （MMP-9） in patients with acute myocardial infarction. Methods A randomized, double- blind, comparison research method was used, 78 patients with acute myocardial infarction were randomly divided into treatment group （taking atorvastatin 20 mg/d for： 14 days）, ordinary group （no atorvastatin, other treatments were similar to treatment group）. Before drug therapy and after two months, IL-18 in serum and MMP-9 levels were measured. Results After 2 months, IL-18 and MMP-9 levels reduced significantly in two groups, IL-18 and MMP- 9 levels in 39 eases of treatment group were less than ordinary group （P 〈 0.05）. Conclusions Atorvastatin significantly reduced IL-18 and MMP-9 levels in patients with acute myocardial inl＇aretion, was new treatment targets for patients with AMI.

关 键 词：心肌梗死 阿托伐他汀 白介素-18 基质金属蛋白酶-9 

分 类 号：R542.22[医药卫生—心血管疾病]